XRP price targets rise as institutions eye $4 and beyond

XRP is hovering in a tight $1.30‑$1.45 band while Standard Chartered’s latest roadmap places $4 as the first major institutional repricing zone before any realistic push toward $10 or higher [1]. The bank’s tiered targets—$2.80 for 2026, $4 by 2026‑27, $7 in 2027 and $12.60 in 2028—frame a step‑wise climb that would require repeated absorption of sell‑side liquidity at each level [1].

The token’s price action remains range‑bound, with attempts to break $1.45‑$1.50 repeatedly stalling and demand resurfacing near $1.38 on dips [1]. Volatility is compressing, and momentum bursts are fading faster than before, suggesting a maturing consolidation phase. Institutional interest is surfacing through XRP‑linked ETFs, which have attracted roughly $1.39 billion in cumulative net inflows and now hold just over $1 billion in assets under management [1]. The inflows are uneven, reflecting early‑stage price discovery rather than aggressive front‑loaded buying.

Regulatory clarity remains the dominant catalyst. The pending CLARITY Act, slated for a Senate markup on May 14 and a potential July 4 signing, could unlock scaled ETF demand. If the bill clears, analysts project cumulative ETF inflows of $3‑5 billion by year‑end, pushing XRP into a $5‑$8 range—a bullish case that would lay the groundwork for longer‑term upside [2]. A delayed or missed vote would keep XRP stuck in its current $1‑$1.50 corridor, postponing any $20 target well beyond 2030 [2].

Bitcoin’s macro‑level movements continue to set the tone for XRP. With crypto market cap above $1.6 trillion and Bitcoin‑linked products drawing about $58 billion in net inflows, a higher‑priced Bitcoin typically rotates liquidity into large‑cap altcoins like XRP, reinforcing the token’s sensitivity to broader market cycles [1].

The real question now is whether XRP can sustain the $4 milestone that Standard Chartered treats as a structural, not speculative, level. Achieving and holding that zone would require continued ETF participation and a favorable regulatory outcome; without those, higher targets such as $10 or $20 remain distant scenarios dependent on multiple intermediate steps.